The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation

BACKGROUND: The CTLA-4 blocking antibody ipilimumab has demonstrated substantial and durable effects in patients with melanoma. While CTLA-4 therapy, both as monotherapy and in combination with PD-1 targeting therapies, has great potential in many indications, the toxicities of the current treatment...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Immunother Cancer
Autori principali: Kvarnhammar, Anne Månsson, Veitonmäki, Niina, Hägerbrand, Karin, Dahlman, Anna, Smith, Karin Enell, Fritzell, Sara, von Schantz, Laura, Thagesson, Mia, Werchau, Doreen, Smedenfors, Kristine, Johansson, Maria, Rosén, Anna, Åberg, Ida, Winnerstam, Magnus, Nyblom, Eva, Barchan, Karin, Furebring, Christina, Norlén, Per, Ellmark, Peter
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2019
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6458634/
https://ncbi.nlm.nih.gov/pubmed/30975201
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0570-8
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi